// App-Quantinova.ai

1387 : Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe

Researchers

Presenter

  • Ran Jin

Principal Investigators

  • Megan Hughes

  • Emily Goddard

  • James Piercy

  • Delphine Courmier

  • Rachael Meadows

  • Waldemar Radziszewski

Medical Centers

  • Adelphi Values, Bollington, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • Sex hormone binding globulin

Drug/Treatment

  • Adalimumab biosimilar

  • ABP 501

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved